What can we expect down the road?
作者信息
Sullivan John
机构信息
Boston University, USA.
出版信息
Nephrol News Issues. 2011 Apr;25(4):28-9.
PMID:21542511
Abstract
摘要
相似文献
1
What can we expect down the road?
Nephrol News Issues. 2011 Apr;25(4):28-9.
2
A glimmer of hope for rural dialysis units.
Nephrol News Issues. 2011 Apr;25(4):29.
3
Erythropoietin & ESRD payments: a promising policy outcome?
Nephrol News Issues. 1989 Sep;3(9):34-5.
4
Surviving change: Can the ESRD provisions in the SCHIP create a level playing field?
Nephrol News Issues. 2007 Sep;21(10):52-3.
5
Medicare and erythropoietin.
N Engl J Med. 2007 Jan 4;356(1):4-6. doi: 10.1056/NEJMp068296.
6
Futuristic plans for ESRD--a new bundled payment system.
Nephrol News Issues. 2005 Sep;19(10):52, 54.
7
Who should be paying for vitamin D analogues--Medicare or the patients?
Nephrol Nurs J. 2006 May-Jun;33(3):345-6, 351.
8
Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
N Engl J Med. 2011 Feb 17;364(7):593-5. doi: 10.1056/NEJMp1014187.
9
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
BMC Nephrol. 2014 Jul 11;15:116. doi: 10.1186/1471-2369-15-116.
10
Medicare program; end-stage renal disease prospective payment system. Final rule.
Fed Regist. 2010 Aug 12;75(155):49029-214.
Zotero 插件